Investor Relations

Business Overview

Pipelines

NanoCarrier's business consists of main pipelines, which are now in clinical study, and newly developed pipelines. Main four products are micellar nanoparticles encapsulating existing potent anticancer agents or their analogues. Therefore, the risk of development is relatively lower than that of new chemical compounds. NanoCarrier aims to expand our business of globally. We aim at global business development maintaining the balance between in-house development and licensing.

Products under development
Main Pipelines

ProductIndicationRegion for
clinical studies
Stage
M
a
j
o
r
p
i
p
e
l
i
n
e
s
Nanoplatin®
(NC-6004)
Pancreatic cancer Japan
Asia
Phase III
clinical study
NSCL, Bladder, Bile Duct cancer USA Phase II
clinical study
Head and Neck cancer

Asia

USA/EU

Phase I
clinical study
DACH-Platin Micelle
(NC-4016)
Cancer
(Note 2)
USA Phase I
clinical study
Epirubicin Micelle
(NC-6300)
Cancer
(Note 2)
Japan Phase I
clinical study
Paclitaxel Micelle
(NK105)(Note 1)
Breast cancer Japan
Asia
Phase III
clinical study
Gastric cancer Japan Phase II
clinical study
completed

New pipelines

Next-Generation platform technology
(Active Targeting)
Development phase
Antibody / Drug Conjugated Micelle
(ADCM)
In house development
ADCM-E7974
(Eisai)
Feasibility Study, etc.
Active - NanoFectTM
Joint Research
siRNA
(Chugai Pharmaceutical)
Feasibility Study, etc.
(Note 1) NK105 is the product development code used for this product at Nippon Kayaku Co., Ltd.
(Note 2) DACH-Platin Micelle (NC-4016) and Epirubicin Micelle are indicated for cancer, but the type(s) of cancer is currently not specified. Specific indications are expected to be determined following future progress in research and development, before the start of phase II clinical studies.

Pagetop